# Table of Contents

## Breaking Advances

5681 Highlights from Recent Cancer Literature

## Review

5683 **DEAR1, a Novel Tumor Suppressor That Regulates Cell Polarity and Epithelial Plasticity**

Nanyue Chen, Seetharaman Balasenthil, Jacquelyn Reuther, and Ann McNeill Killary

## Integrated Systems and Technologies

5690 **Novel Drug Candidates for the Treatment of Metastatic Colorectal Cancer through Global Inverse Gene-Expression Profiling**

Vera van Noort, Sebastian Schölch, Murat Iskar, Georg Zeller, Kristina Ostertag, Christine Schweitzer, Kristin Werner, Jürgen Weitz, Moritz Koch, and Peer Bork

**Précis:** These findings provide a rationale to reposition the antidepressant drug citalopram for treatment of late-stage colorectal cancers, with immediate implications for clinical evaluation of this drug.

5700 **Development of Novel ADCs: Conjugation of Tubulysin Analogues to Trastuzumab Monitored by Dual Radiolabeling**

Ruth Cohen, Danielle J. Vugts, Gerard W.M. Visser, Marijke Stigtger-van Walsum, Marije Bolijn, Marco Spiga, Paolo Lazzari, Sreejith Shankar, Monica Sani, Matteo Zanda, and Guus A.M.S. van Dongen

**Précis:** Radiolabeling both a synthetic tubulysin and the antibody to which it is attached facilitated preclinical validation of a new antibody-drug conjugate (ADC) with excellent tumor-targeting performance and efficacy.

## Microenvironment and Immunology

5711 **Adiponectin Receptor Signaling on Dendritic Cells Blunts Antitumor Immunity**

Peng H. Tan, Helen E.J. Tyrrell, Liquan Gao, Danmei Xu, Jianchao Quan, Dipender Gill, Lena Rai, Yunchuan Ding, Gareth Plant, Yuan Chen, John Z. Xue, Ashok I. Handa, Michael J. Greenall, Kenneth Walsh, and Shao-An Xue

**Précis:** Novel adiponectin signaling pathways revealed in this report are shown to promote immune tolerance signals in dendritic cells that drive tumoral immune escape in cancer, suggesting broadly applicable new strategies for the immunometabolic control of cancer.

5723 **HMGB1 Enhances Immune Suppression by Facilitating the Differentiation and Suppressive Activity of Myeloid-Derived Suppressor Cells**

Katherine H. Parker, Pratima Sinha, Lucas A. Horn, Virginia K. Clements, Huan Yang, Jianhua Li, Kevin J. Tracey, and Suzanne Ostrand-Rosenberg

**Précis:** A secreted alarmin that is ubiquitously present in the tumor microenvironment provides a pivotal proinflammatory contribution to the differentiation and suppressive potency of myeloid-derived suppressor cells, an important driver of immune escape in many solid tumors.

5734 **Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy**

Jing Huang, Lin Xiao, Xiaoting Gong, Wenwei Shao, Yanhui Yin, Qinyuan Liao, Yang Meng, Yingmei Zhang, Dalong Ma, and Xiaoyan Qiu

**Précis:** These findings offer strong evidence for a new member of the yc cytokine family that provides powerful support for CD8+ T-cell-mediated immunity, with potential implications for therapeutic applications.

## Molecular and Cellular Pathobiology

5746 **Metastatic Consequences of Immune Escape from NK Cell Cytotoxicity by Human Breast Cancer Stem Cells**

Bin Wang, Qiang Wang, Zhe Wang, Jun Jiang, Shi-Cang Yu, Yi-Fang Ping, Jing Yang, Sen-Lin Xu, Xian-Zong Ye, Chuan Xu, Lang Yang, Cheng Qian, Ji Ming Wang, You-Hong Cui, Xia Zhang, and Xiu-Wu Bian

**Précis:** These findings reveal how metastasis-initiating breast cancer stem-like cells evade immune surveillance by natural killer cells.

5758 **Cellular Disposal of miR23b by RAB27-Dependent Exosome Release Is Linked to Acquisition of Metastatic Properties**


**Précis:** This interesting study suggests that exosome secretion serves as a disposal mechanism for tumor suppressor microRNA during tumor progression, thereby enabling the acquisition of metastatic capabilities.
5772  AEG-1 Promoter–Mediated Imaging of Prostate Cancer
Akriti Bhatnagar, Yuchuan Wang, Ronnie C. Mease, Matthew Gabrielson, Polina Sysa, II Minn, Gilbert Green, Brian Simmons, Kathleen Gabrielson, Siddik Sarkar, Paul B. Fisher, and Martin G. Pomper

Preciso: This study offers a sensitive, specific, and noninvasive method to image prostate cancer, including in bone metastases that lack a reliable clinical imaging agent, offering a preclinical proof of concept that rationalizes immediate clinical translation and evaluation in patients with advanced prostate cancer.

5782  Mycoplasma Hyorhinis Infection Promotes NF-kB–Dependent Migration of Gastric Cancer Cells
Hongying Duan, Ling Chen, Like Qu, Hua Yang, Sonya Wei Song, Yong Han, Meihua Ye, Wanyuan Chen, Xianglei He, and Chengchao Shou

Preciso: These findings unveil the effect of a mycoplasmic infection that has been linked to stomach cancer and other types of cancer but not understood in terms of its possible functional contributions, as revealed for the first time in this study.

5795  PCTAIRE1 Phosphorylates p27 and Regulates Mitosis in Cancer Cells
Teruki Yanagi, Maryla Krajewska, Shu-ichi Matsuzawa, and John C. Reed

Preciso: These results reveal an unexpected role for the distant CDK relative PCTAIRE1 in cancer cell division and other types of cancer but not understood in terms of its possible functional contributions, as revealed for the first time in this study.

THERAPEUTICS, TARGETS, AND CHEMICAL BIOLOGY

5819  Copper Signaling Axis as a Target for Prostate Cancer Therapeutics

Preciso: Clinical trials in oncology of an approved diethio compound have failed to produce efficacy, but the findings of this study suggest that this compound should be reexplored with the addition of copper to the regimen, particularly with regard to treatment of prostate cancers resistant to androgen ablation.

5832  Metabolic Vulnerabilities in Endometrial Cancer

Preciso: This study reveals that the survival of endometrial cancer cells relies critically on GLUT6-mediated glucose transport, along with glycolytic and lipogenic metabolic pathways, with implications for therapeutic strategies in this setting.
In Vivo Localization of \(^{90}\)Y and \(^{177}\)Lu Radioimmunoconjugates Using Cerenkov Luminescence Imaging in a Disseminated Murine Leukemia Model
Ethan R. Balkin, Aimee Kenoyer, Johnnie J. Orozco, Alexandra Hernandez, Maziyar Shadman, Darrell R. Fisher, Damian J. Green, Mark D. Hylarides, Oliver W. Press, D. Scott Wilbur, and John M. Pagel

Précis: Results demonstrate the feasibility of using a novel noninvasive imaging technique called Cerenkov Light Imaging (CLI) to optimize the use of radioimmunoconjugates used to treat aggressive leukemias.

SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression
Shaomeng Wang, Wei Sun, Yujun Zhao, Donna McEachern, Isabelle Meaux, Cédric Barrière, Jeanne A. Stuckey, Jennifer L. Meagher, Longchuan Bai, Liu Liu, Cassandra Gianna Hoffman-Luca, Jianfeng Lu, Sanjeev Shangary, Shanghai Yu, Denzil Bernard, Angelo Aguilar, Odette Dos-Santos, Laurent Besret, Stéphane Guerif, Pascal Pannier, Dimitri Gorge-Bernat, and Laurent Debussche

Précis: Despite the risk of applying a selection for p53 mutations that escape MDM2 control, blocking MDM2–p53 protein–protein interaction has long been considered by many to offer an attractive cancer therapeutic strategy, a position strongly supported by the findings of this preclinical study.

Dsh Homolog DVL3 Mediates Resistance to IGFIR Inhibition by Regulating IGF-RAS Signaling
Shan Gao, Ilirjana Bajrami, Clare Verrill, Asha Kigozi, Djamilâ Ouatet, Tamara Aleksic, Ruth Asher, Cheng Han, Paul Allen, Deborah Bailey, Stephan Keller, Takeshi Kashima, Nicholas Athanasou, Jean-Yves Blay, Sandra Schmitz, Jean-Pascal Machiels, Nav Upile, Terry M. Jones, George Thalmann, Shazad Q. Ashraf, Jennifer L. Wilding, Walter F. Bodmer, Mark R. Middleton, Alan Ashworth, Christopher J. Lord, and Valentine M. Macaulay

Précis: This mechanistic study is important because it addresses the lack of predictive biomarkers for stratifying and recruiting cancer patients who might benefit from IGF-1 inhibitors, a key gap in their clinical development as cancer drugs.

AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
Catherine Wilson, Xiaofen Ye, Thinh Pham, Eva Lin, Sara Chan, Erin McNamara, Richard M. Nevè, Lisa Belmont, Hartmut Koeppen, Robert L. Yauch, Avi Ashkenazi, and Jeff Settleman

Précis: These findings challenge a purported role for AXL in drug resistance while offering a novel rationale to combine AXL-targeting drugs with antimitotic agents to eradicate invasive cancers.

\(\beta\)-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations

Précis: Drug resistance to EGF receptor antagonists in lung cancer may be mediated in part by activation of the \(\beta\)-catenin pathway, reinforcing its importance as an oncogenic driver in this setting.

MYC Activates Stem-like Cell Potential in Hepatocarcinoma by a p53-Dependent Mechanism
Hirofumi Akita, Jens U. Marquardt, Marian E. Durkin, Mitsuteru Kitade, Daekwan Seo, Elizabeth A. Conner, Jesper B. Andersen, Valentina M. Factor, and Snorri S. Thorgerisson

Précis: Cancer stem-like cell populations in liver cancer appear to be expanded under conditions in which MYC is activated and p53 is downregulated, with potential implications for understanding etiology, progression, and treatment in this disease.

Zfx Facilitates Tumorigenesis Caused by Activation of the Hedgehog Pathway
Colin J. Palmer, Jose M. Galan-Caridad, Stuart P. Weisberg, Liang Lei, Jose M. Esquilin, Gist F. Croft, Brandon Wainwright, Peter Canoll, David M. Owens, and Boris Reizis

Précis: This preclinical genetic study identifies new candidate targets for the control of tumors driven by the Hedgehog pathway, the aberrant activation of which has been implicated widely in many types of human solid tumors.
SIRT6 Promotes COX-2 Expression and Acts as an Oncogene in Skin Cancer
Mei Ming, Weinong Han, Baozhong Zhao, Nagalingam R. Sundaresan, Chu-Xia Deng, Mahesh P. Gupta, and Yu-Ying He

Précis: This study challenges an existing view of the Sirt2-related protein SIRT6 as a tumor suppressor, finding instead in a genetically deficient mouse that it functions as an oncogene in the skin epidermis.

ABOUT THE COVER

The AXL receptor tyrosine kinase has been implicated as a cellular signaling protein that is specifically upregulated in the context of the epithelial-to-mesenchymal transformation seen in some epithelial cancers and the emergence of acquired drug resistance. Among the tumor types in which a mesenchymal, largely drug-refractory phenotype appears to be prevalent is triple-negative breast cancer (TNBC). This immunohistological image illustrates the expression of AXL in a TNBC tumor specimen, revealing punctate cytoplasmic staining of AXL in tumor cells as well as focal vascular staining. For details, see article by Wilson and colleagues on page 5878.
74 (20)


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/74/20

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.